Article information
Full text is only aviable in PDF
Bibliografía
[1.]
L. Reid.
Natural history of mucus in the bronchial tree.
Arch Environ Health, 10 (1965), pp. 265-273
[2.]
S. Girod, J.M. Zahm, C. Plotkowski, G. Beck, E. Puchelle.
Role of physiochemical properties of mucus in the protection of the respiratory epithelium.
Eur Respir J, 5 (1992), pp. 477-487
[3.]
A. Wanner.
The role of mucus in chronic obstructive pulmonary disease.
Chest, 97 (1990), pp. 11-15
[4.]
C.H. Fanta.
Clinical aspects of mucus and mucous plugging in asthma.
J Asthma, 22 (1985), pp. 295-301
[5.]
E. Puchelle, S. De Bentzmann, J.M. Zahm.
Physical and functional properties of airway secretions in cystic fibrosis. therapeutic approaches.
Respiration, 62 (1995), pp. 2-12
[6.]
Task Group on Mucoactive Drugs.
Recommendations for guidelines on clinical trials on mucoactive drugs in chronic bronchitis and chronic obstructive pulmonary disease.
Chest, 106 (1994), pp. 1.532-1.537
[7.]
C.D. Mulrow.
The medical review article: State of the Science.
Ann Intern Med, 106 (1987), pp. 485-488
[8.]
N.C.G. Hansen, A. Skriver, L. Brorsen-Riis, S. Balsløv, T. Evald, N. Maltbaek, et al.
Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis.
Respir Med, 88 (1994), pp. 531-535
[9.]
G. Boman, U. Bäcker, S. Larsson, B. Melander, L. Wáhlander.
Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: a report of a trial organized by the Swedish Society for Pulmonary Diseases.
Eur J Respir Dis, 64 (1983), pp. 405-415
[10.]
Multicenter Study Group.
Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study.
Eur J Respir Dis, 61 (1980), pp. 93-108
[11.]
J.B. Rasmussen, C. Glennow.
Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.
Eur Respir J, 1 (1988), pp. 351-355
[12.]
I.M. Jackson, J. Barnes, P. Cooksey.
Efficacy and tolerability of oral acetylcysteine (Fabrol®) in chronic bronchitis: a double-blind placebo controlled study.
J Int Med Res, 12 (1984), pp. 198-206
[13.]
British Thoracic Society Research Committee.
Oral N-acetilcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction.
Thorax, 40 (1985), pp. 832-835
[14.]
Medical Research Council.
Definition and classification of chronic bronchitis for clinical and epidemiological purposes.
Lancet, 1 (1965), pp. 775-779
[15.]
C.M. Fletcher, R. Peto, C.M. Tinker, F.E. Speizer.
The natural history of chronic bronchitis and emphysema.
Oxford University Press, (1976),
[16.]
G.D. Parr, A. Huitson.
Oral Fabrol (oral N-acetylcysteine) in chronic bronchitis.
Br J Dis Chest, 81 (1987), pp. 341-348
[17.]
D.P. Goldberg.
The detection of psychiatric illness by questionnaire. A technique for the identification and assessment of non-psychotic psychiatric illness.
Institute of Psychiatric Maudsley Monographs, número 21, Oxford University Press, (1972),
[18.]
H. Brocard, J. Charpin, J. Germouty.
Acute indications for acetylcysteine. Etude multi-centrique en double aveugle avec acétylcystéine orale vs placébo.
Eur J Respir Dis, 61 (1980), pp. 65-69
[19.]
S. Jepsen, A. Klaerke, P.H. Nielsen, S.T. Nielsen, O. Simonsen.
Systemic administration of N-acetylcysteine has no effect on postoperative lung function following elective upper laparotomy in lung healthy patients.
Acta Anaesthesiol Scand, 33 (1989), pp. 219-222
[20.]
S. Valenti, G. Marenco.
Italian multicenter study on the treatment of chronic obstructive lung disease with bromhexine. A doubleblind placebo-controlled trial.
Respiration, 56 (1989), pp. 11-15
[21.]
D. Olivieri, A. Ciaccia, E. Marangio, S. Marsico, T. Todisco, M. Del Vita.
Role of bromhexine in exacerbations of bronchiectasis. Double-blind randomized multicenter study versus placebo.
Respiration, 58 (1991), pp. 117-121
[22.]
T.L. Petty.
The National Mucolytic Study.
Results of a randomized, double-blind placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest, 97 (1990), pp. 75-83
[23.]
G.H. Guyatt, M. Townsend, F. Kazim, M.T. Newhose.
A controlled trial of ambroxol in chronic bronchitis.
Chest, 92 (1987), pp. 618-620
[24.]
D. Olivieri, G. Zavattini, G. Tomasini, S. Daniotti, G. Bonsignore, G. Ferrara, et al.
Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo.
Respiration, 51 (1987), pp. 42-51
[25.]
J. Germouty, J.L. Jirou-Najou.
Clinical efficacy of ambroxol in the treatment of bronchial stasis. Clinical trial in 120 patients at two diferent doses.
Respiration, 51 (1987), pp. 37-41
[26.]
G. Fegiz, P. Volpino, G. Piat, V. Cangemi, F. Morino, V. Festa, et al.
Prevention by ambroxol of bronchopulmonary complications after upper abdominal surgery: double blind italian multicenter clinical study versus placebo.
Lung, 169 (1991), pp. 69-76
[27.]
E.G. Jager.
Double-blind, placebo-controlled clinical evaluation of guaimesal in outpatients.
Clin Ther, 11 (1989), pp. 341-362
[28.]
H.J. Fuchs, D.S. Borowitz, D.H. Christiasen, E.M. Morris, M.L. Nash, B.W. Ramsey, et al.
Effect of aerosolized recombinant human DNAse on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis.
N Engl J Med, 331 (1994), pp. 637-642
[29.]
J.M. Polu, F. Chabot, B. Wallaert.
Mucomodificateurs bronchiques, antioxydants et antiprotéases.
Rev Mal Respir, 10 (1993), pp. 87-100
[30.]
M. Salathe, T.G. O’Riordan, A. Wanner.
Treatment of mucociliary dysfunction.
Chest, 110 (1996), pp. 1.048-1.057
[31.]
D. Pavia, P.P. Sutton, M.T. López-Vidriero, J.E. Agnew, S.W. Clarke.
Drug effects on mucociliary function.
Eur J Respir Dis, 64 (1983), pp. 304-317
[32.]
D. Pavia.
The role of chest physiotherapy in mucus hypersecretion.
Lung, 168 (1990), pp. 614-621
[33.]
G.H. Guyatt, M.T. Newhouse.
Rigorous evaluation. Greater need than ever [editorial].
Chest, 9 (1987), pp. 580-581
[34.]
A. Lurie, M. Mestiri, G. Fluchon, J. Marsac, A. Lockhart, G. Strauch.
Methods for clinical assessment of expectorants: a critical review.
Int J Clin Pharmacol Res, 12 (1992), pp. 47-52
[35.]
C.L. Van Herwaarden, A. Bast, P.N. Dekhuijzen.
The role of Nacetylcarbocysteine in the treatment of chronic obstructive pulmonary disease.
Neth J Med, 47 (1995), pp. 45-48
[36.]
B.G. Disse.
The pharmacology of ambroxol review and new results.
Eur J Respir Dis, 71 (1987), pp. 255-262
[37.]
P.C. Braga, L. Allegra, R. Bossi, R. Scuri, C.L. Castiglioni, S. Romandini.
Review on sobrerol as a muco-modifying drug: experimental data and clinical findings in hypersecretory bronchopulmonary diseases.
Int J Clin Pharmacol Res, 7 (1987), pp. 381-400
[38.]
M.E. Hodson.
Aerosolized domase alfa (rh DNAse) for therapy of cystic fibrosis.
Am J Respir Crit Care Med, 151 (1995), pp. 70-74
[40.]
F. Manresa.
Use of mucolytics in acute exacerbations of chronic obstructive pulmonary disease.
Eur Respir Rev, 2 (1992), pp. 286-289
[41.]
P.J. Wills, T. Wodehouse, K. Corkery, K. Mallon, R. Wilson, P.J. Cole.
Short-term recombinant human DNase in bronchiectasis.
Am J Respir Crit Care Med, 154 (1996), pp. 413-417
Copyright © 1998. Sociedad Española de Neumología y Cirugía Torácica
